Hiroaki Ikushima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hiroaki Ikushima has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Hidenori Kage
Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
16 shared publications - Katsutoshi Oda
Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
9 shared publications - Kousuke Watanabe
Next-Generation Precision Medicine Development Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
8 shared publications Akihisa Mitani
Department of Respiratory Medicine Graduate School of Medicine, The University of Tokyo Tokyo Japan
4 shared publications- Koki Fujii
Department of Respiratory Medicine, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
4 shared publications Kousuke Watanabe
Next‐Generation Precision Medicine Development Laboratory Graduate School of Medicine, The University of Tokyo Tokyo Japan
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (11)
KRAS G12Y Causing a False‐Positive KRAS G12C Result With an Indistinguishable PCR Pattern in Lung Adenocarcinoma
KRAS G12C is an actionable alteration in non‐small cell lung cancer, making accurate molecular identification essential for treatment selection. A 61‐year‐old man with metastatic lung adenocarcinoma showed a KRAS G12C‐positive reaction on the AmoyDx Pan Lung Cancer PCR Panel (AmoyDx PLC panel). After progression on first‐line chemoimmunotherapy, sotorasib was administered, but progressive disease was observed at the first radiologic assessment. Subsequent NGS‐based comprehensive genomic profiling of the same pretreatment FFPE block identified KRAS G12Y (c.34_35delinsTA; variant allele frequency, 25.8%), with no sequence reads supporting KRAS G12C. This prompted suspicion of a false‐positive PCR result. Repeat AmoyDx PLC panel testing reproduced the G12C‐positive reaction and testing of a KRAS G12Y plasmid likewise yielded a G12C‐positive reaction without additional KRAS‐associated signals, confirming cross‐reactivity. KRAS G12Y can therefore mimic genuine KRAS G12C in mutation‐specific PCR testing and may lead to inappropriate genotype‐directed therapy.
- 2 November 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (11)
Open AccessKRAS G12Y Causing a False‐Positive KRAS G12C Result With an Indistinguishable PCR Pattern in Lung Adenocarcinoma
KRAS G12C is an actionable alteration in non‐small cell lung cancer, making accurate molecular identification essential for treatment selection. A 61‐year‐old man with metastatic lung adenocarcinoma showed a KRAS G12C‐positive reaction on the AmoyDx Pan Lung Cancer PCR Panel (AmoyDx PLC panel). After progression on first‐line chemoimmunotherapy, sotorasib was administered, but progressive disease was observed at the first radiologic assessment. Subsequent NGS‐based comprehensive genomic profiling of the same pretreatment FFPE block identified KRAS G12Y (c.34_35delinsTA; variant allele frequency, 25.8%), with no sequence reads supporting KRAS G12C. This prompted suspicion of a false‐positive PCR result. Repeat AmoyDx PLC panel testing reproduced the G12C‐positive reaction and testing of a KRAS G12Y plasmid likewise yielded a G12C‐positive reaction without additional KRAS‐associated signals, confirming cross‐reactivity. KRAS G12Y can therefore mimic genuine KRAS G12C in mutation‐specific PCR testing and may lead to inappropriate genotype‐directed therapy.
- Open Access
- 30 October 2026
- Published by Elsevier in SSRN Electronic Journal
Therapeutic Yield of Comprehensive Genomic Profiling After Osimertinib Discontinuation in EGFR-Mutated Non–Small Cell Lung Cancer
Background: Comprehensive genomic profiling (CGP) after osimertinib may identify potentially targetable resistance-associated alterations in patients with EGFR-mutated non–small cell lung cancer (NSCLC). However, their translation into genotype-matched treatment in routine clinical practice remains unclear.Patients and Methods: We retrospectively analyzed patients with EGFR-mutated NSCLC in Japan’s nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database who underwent CGP after osimertinib discontinuation. Potentially targetable non-EGFR alterations were prespecified. We assessed their detection, expert-panel (EP) recommendations, treatment implementation, and genotype matching. Factors associated with detection were evaluated using multivariable logistic regression.Results: Among 477 patients, potentially targetable non-EGFR alterations were identified in 73 (15.3%). An EP therapeutic option was presented for 56 (76.7%), and an EP-presented therapy was administered in 21 (28.8%). Genotype-matched non-EGFR therapy was administered in 15 patients (20.5% of those with a potentially targetable alteration; 3.1% overall). Genotype-matched therapy was administered to 5 of 7 patients (71.4%) with BRAF V600 alterations and 5 of 6 (83.3%) with RET rearrangements, but only 1 of 37 (2.7%) with MET amplification and 1 of 18 (5.6%) with ERBB2 amplification. Tissue-based CGP was associated with a higher likelihood of detecting potentially targetable non-EGFR alterations than liquid-based CGP (adjusted odds ratio, 4.07; 95% confidence interval, 2.32–7.14; P < 0.001).Conclusions: CGP after osimertinib discontinuation identified potentially targetable non-EGFR alterations in a subset of patients, but only a small proportion received genotype-matched therapy. The therapeutic yield may depend not only on target detection but also on translation into genotype-matched treatment in routine clinical practice.
- 30 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTherapeutic Yield of Comprehensive Genomic Profiling After Osimertinib Discontinuation in EGFR-Mutated Non–Small Cell Lung Cancer
Background: Comprehensive genomic profiling (CGP) after osimertinib may identify potentially targetable resistance-associated alterations in patients with EGFR-mutated non–small cell lung cancer (NSCLC). However, their translation into genotype-matched treatment in routine clinical practice remains unclear.Patients and Methods: We retrospectively analyzed patients with EGFR-mutated NSCLC in Japan’s nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database who underwent CGP after osimertinib discontinuation. Potentially targetable non-EGFR alterations were prespecified. We assessed their detection, expert-panel (EP) recommendations, treatment implementation, and genotype matching. Factors associated with detection were evaluated using multivariable logistic regression.Results: Among 477 patients, potentially targetable non-EGFR alterations were identified in 73 (15.3%). An EP therapeutic option was presented for 56 (76.7%), and an EP-presented therapy was administered in 21 (28.8%). Genotype-matched non-EGFR therapy was administered in 15 patients (20.5% of those with a potentially targetable alteration; 3.1% overall). Genotype-matched therapy was administered to 5 of 7 patients (71.4%) with BRAF V600 alterations and 5 of 6 (83.3%) with RET rearrangements, but only 1 of 37 (2.7%) with MET amplification and 1 of 18 (5.6%) with ERBB2 amplification. Tissue-based CGP was associated with a higher likelihood of detecting potentially targetable non-EGFR alterations than liquid-based CGP (adjusted odds ratio, 4.07; 95% confidence interval, 2.32–7.14; P < 0.001).Conclusions: CGP after osimertinib discontinuation identified potentially targetable non-EGFR alterations in a subset of patients, but only a small proportion received genotype-matched therapy. The therapeutic yield may depend not only on target detection but also on translation into genotype-matched treatment in routine clinical practice.
- Open Access
- 15 September 2026
- Published by Elsevier in Lung Cancer
- Vol. 221
Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC
- 15 September 2026
- Published by Elsevier in Lung Cancer
- Vol. 221
Open AccessStandard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC
- Open Access
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Standard Targeted Therapy Implementation for Driver Alterations Newly Identified by Comprehensive Genomic Profiling in Clinically Driver-Negative Advanced NSCLC
Background: Comprehensive genomic profiling (CGP) can identify oncogenic drivers missed by routine molecular testing in advanced or recurrent non-small cell lung cancer (NSCLC). However, the availability of standard targeted therapy, treatment implementation, and survival relevance of these CGP-identified new drivers remain unclear.Methods: Using the nationwide Center for Cancer Genomics and Advanced Therapeutics database, we analyzed patients with advanced or recurrent NSCLC without clinically known driver alterations before CGP. CGP-identified new drivers were classified as actionable or non-actionable according to standard targeted therapy availability in Japan. We evaluated prevalence, treatment implementation, and overall survival (OS) from CGP registration.Results: Among 2,296 patients, 855 had CGP-identified new drivers, of whom 495 (57.9%) had actionable alterations. Matched targeted therapy was administered to 191 patients with actionable alterations (38.6%) and to 84.5% of those with documented post-CGP systemic therapy. Median OS was longest in patients with actionable CGP-identified new drivers, followed by driver-negative patients and those with non-actionable CGP-identified new drivers (18.9, 11.4, and 10.2 months, respectively; log-rank P < 0.001). In multivariable analysis, actionable CGP-identified new drivers were associated with longer OS than driver-negative status (adjusted hazard ratio, 0.71; 95% confidence interval, 0.59–0.84; P < 0.001), whereas non-actionable new drivers were not. Sensitivity analyses using time-specific drug-availability definitions yielded consistent findings.Conclusions: CGP identified new drivers with available standard targeted therapy in patients with advanced or recurrent NSCLC. The clinical relevance of CGP-identified new driver detection appears linked to standard targeted therapy availability and translation of actionable findings into matched therapy.
- 16 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessStandard Targeted Therapy Implementation for Driver Alterations Newly Identified by Comprehensive Genomic Profiling in Clinically Driver-Negative Advanced NSCLC
Background: Comprehensive genomic profiling (CGP) can identify oncogenic drivers missed by routine molecular testing in advanced or recurrent non-small cell lung cancer (NSCLC). However, the availability of standard targeted therapy, treatment implementation, and survival relevance of these CGP-identified new drivers remain unclear.Methods: Using the nationwide Center for Cancer Genomics and Advanced Therapeutics database, we analyzed patients with advanced or recurrent NSCLC without clinically known driver alterations before CGP. CGP-identified new drivers were classified as actionable or non-actionable according to standard targeted therapy availability in Japan. We evaluated prevalence, treatment implementation, and overall survival (OS) from CGP registration.Results: Among 2,296 patients, 855 had CGP-identified new drivers, of whom 495 (57.9%) had actionable alterations. Matched targeted therapy was administered to 191 patients with actionable alterations (38.6%) and to 84.5% of those with documented post-CGP systemic therapy. Median OS was longest in patients with actionable CGP-identified new drivers, followed by driver-negative patients and those with non-actionable CGP-identified new drivers (18.9, 11.4, and 10.2 months, respectively; log-rank P < 0.001). In multivariable analysis, actionable CGP-identified new drivers were associated with longer OS than driver-negative status (adjusted hazard ratio, 0.71; 95% confidence interval, 0.59–0.84; P < 0.001), whereas non-actionable new drivers were not. Sensitivity analyses using time-specific drug-availability definitions yielded consistent findings.Conclusions: CGP identified new drivers with available standard targeted therapy in patients with advanced or recurrent NSCLC. The clinical relevance of CGP-identified new driver detection appears linked to standard targeted therapy availability and translation of actionable findings into matched therapy.
- Open Access
- 10 June 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (6) , e70648
Isolated Subcarinal Lymph Node Recurrence 24 Years After Treatment for Primary Tracheal Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is a slow‐growing malignancy characterised by late recurrence, making long‐term follow‐up essential. We report a case of 55‐year‐old woman who presented with exudative right pleural effusion and subcarinal lymphadenopathy after haematopoietic stem cell transplantation for myelofibrosis. She had undergone surgery and radiotherapy for primary tracheal ACC 24 years prior. Although haematologic disease‐related conditions were initially suspected, endobronchial ultrasound‐guided transbronchial needle aspiration of the subcarinal lymph node revealed isolated recurrence of ACC, with no evidence of pleural malignancy on pleural biopsy results. Because ACC progresses more slowly than many other malignancies, the growth rate alone does not reliably distinguish benign from malignant lesions. Therefore, a history of ACC should always be considered, and a tissue diagnosis should be pursued when clinically indicated.
- 10 June 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (6) , e70648
Open AccessIsolated Subcarinal Lymph Node Recurrence 24 Years After Treatment for Primary Tracheal Adenoid Cystic Carcinoma
Adenoid cystic carcinoma (ACC) is a slow‐growing malignancy characterised by late recurrence, making long‐term follow‐up essential. We report a case of 55‐year‐old woman who presented with exudative right pleural effusion and subcarinal lymphadenopathy after haematopoietic stem cell transplantation for myelofibrosis. She had undergone surgery and radiotherapy for primary tracheal ACC 24 years prior. Although haematologic disease‐related conditions were initially suspected, endobronchial ultrasound‐guided transbronchial needle aspiration of the subcarinal lymph node revealed isolated recurrence of ACC, with no evidence of pleural malignancy on pleural biopsy results. Because ACC progresses more slowly than many other malignancies, the growth rate alone does not reliably distinguish benign from malignant lesions. Therefore, a history of ACC should always be considered, and a tissue diagnosis should be pursued when clinically indicated.
- Open Access
- 3 June 2026
- Published by Elsevier in International Journal of Lung Cancer
- Vol. 1 (3)
Clinical utility of comprehensive genomic profiling in detecting actionable EGFR exon 20 insertions undetected by companion diagnostics: a case report
- 3 June 2026
- Published by Elsevier in International Journal of Lung Cancer
- Vol. 1 (3)
Open AccessClinical utility of comprehensive genomic profiling in detecting actionable EGFR exon 20 insertions undetected by companion diagnostics: a case report
- Open Access
- 26 May 2026
- Published by Wiley in Cancer Science
- Vol. 117 (8) , 2085-2097
MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy
The homozygous deletion of the chromosome 9p21.3 locus, which includes cyclin‐dependent kinase inhibitor 2A/B ( CDKN2A/B ) and methylthioadenosine phosphorylase ( MTAP ) genes, is one of the most common genomic alterations in cancer. MTAP encodes an essential enzyme in the methionine salvage pathway. Historically, deletions at this locus have been characterized primarily by cell cycle dysregulation driven by CDKN2A/B loss. However, recent studies have revealed that the co‐deletion of MTAP exposes profound metabolic vulnerabilities. Loss of the MTAP function increases cellular dependency on protein arginine methyltransferase 5 (PRMT5). Consequently, targeted PRMT5 inhibition effectively induces synthetic lethality specifically in MTAP ‐deleted tumors. Based on this unique mechanism, the development of novel therapeutic agents exploiting this synthetic lethality is actively underway. In this review, we provide a comprehensive overview of the physiological roles of the MTAP‐PRMT5 axis and the mechanistic principles underlying this synthetic lethality in MTAP ‐deficient cells. Furthermore, drawing upon insights from the analysis of real‐world patient data, we discuss the clinical and molecular characteristics of MTAP ‐deleted tumors, review the landscape of ongoing clinical trials, and explore novel therapeutic strategies.
- 26 May 2026
- Published by Wiley in Cancer Science
- Vol. 117 (8) , 2085-2097
Open AccessMTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy
The homozygous deletion of the chromosome 9p21.3 locus, which includes cyclin‐dependent kinase inhibitor 2A/B ( CDKN2A/B ) and methylthioadenosine phosphorylase ( MTAP ) genes, is one of the most common genomic alterations in cancer. MTAP encodes an essential enzyme in the methionine salvage pathway. Historically, deletions at this locus have been characterized primarily by cell cycle dysregulation driven by CDKN2A/B loss. However, recent studies have revealed that the co‐deletion of MTAP exposes profound metabolic vulnerabilities. Loss of the MTAP function increases cellular dependency on protein arginine methyltransferase 5 (PRMT5). Consequently, targeted PRMT5 inhibition effectively induces synthetic lethality specifically in MTAP ‐deleted tumors. Based on this unique mechanism, the development of novel therapeutic agents exploiting this synthetic lethality is actively underway. In this review, we provide a comprehensive overview of the physiological roles of the MTAP‐PRMT5 axis and the mechanistic principles underlying this synthetic lethality in MTAP ‐deficient cells. Furthermore, drawing upon insights from the analysis of real‐world patient data, we discuss the clinical and molecular characteristics of MTAP ‐deleted tumors, review the landscape of ongoing clinical trials, and explore novel therapeutic strategies.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2600100
Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations
PURPOSE: Methylthioadenosine phosphorylase ( MTAP ) deletion represents a promising therapeutic vulnerability through synthetic lethality. However, the clinical and molecular context of MTAP -deleted thoracic tumors, particularly with respect to actionable oncogenic drivers and immune checkpoint inhibitor efficacy, remains incompletely defined across diverse populations. METHODS: We analyzed clinicogenomic data from two nationwide cohorts: AACR Project GENIE (United States; n = 11,091 evaluable samples) and Center for Cancer Genomics and Advanced Therapeutics (C-CAT; Japan; n = 4,851). MTAP copy number was assessed in lung, pleural, and thymic tumors. We evaluated histology-specific prevalence, comutational patterns, associations with actionable genomic alterations, tumor mutational burden (TMB), and overall survival (OS) in selected molecular subgroups. RESULTS: In lung cancer, MTAP deletion occurred at comparable frequencies between adenocarcinoma and squamous cell carcinoma within each cohort (GENIE: 8.1% v 9.8%; C-CAT: 19.6% v 16.5%) but was rare in small cell lung cancer (GENIE: 1.0%; C-CAT: 1.9%). In thymic tumors, MTAP deletion was observed predominantly in thymic carcinoma and was uncommon in thymoma. MTAP deletion was strongly associated with CDKN2A/B deletions and was rare in their absence. MTAP deletion frequently coexisted with actionable driver alterations, including EGFR mutations, ALK fusions, and ERBB2 alterations. A robust inverse association with RB1 mutations was observed in both cohorts. Although MTAP deletion appeared associated with lower TMB ( P < .01) and shorter OS in EGFR -mutated lung cancer (median 18.5 v 31.4 months, P < .01), these associations were largely attributable to enrichment of oncogenic drivers and concurrent CDKN2A loss, respectively. CONCLUSION: MTAP -deleted thoracic tumors exhibit reproducible clinical and molecular features across populations. Our findings support the rational, globally applicable development of MTAP -targeted synthetic lethal strategies in thoracic malignancies, particularly in combination with molecular targeted agents.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2600100
Clinicogenomic Landscape of MTAP -Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations
PURPOSE: Methylthioadenosine phosphorylase ( MTAP ) deletion represents a promising therapeutic vulnerability through synthetic lethality. However, the clinical and molecular context of MTAP -deleted thoracic tumors, particularly with respect to actionable oncogenic drivers and immune checkpoint inhibitor efficacy, remains incompletely defined across diverse populations. METHODS: We analyzed clinicogenomic data from two nationwide cohorts: AACR Project GENIE (United States; n = 11,091 evaluable samples) and Center for Cancer Genomics and Advanced Therapeutics (C-CAT; Japan; n = 4,851). MTAP copy number was assessed in lung, pleural, and thymic tumors. We evaluated histology-specific prevalence, comutational patterns, associations with actionable genomic alterations, tumor mutational burden (TMB), and overall survival (OS) in selected molecular subgroups. RESULTS: In lung cancer, MTAP deletion occurred at comparable frequencies between adenocarcinoma and squamous cell carcinoma within each cohort (GENIE: 8.1% v 9.8%; C-CAT: 19.6% v 16.5%) but was rare in small cell lung cancer (GENIE: 1.0%; C-CAT: 1.9%). In thymic tumors, MTAP deletion was observed predominantly in thymic carcinoma and was uncommon in thymoma. MTAP deletion was strongly associated with CDKN2A/B deletions and was rare in their absence. MTAP deletion frequently coexisted with actionable driver alterations, including EGFR mutations, ALK fusions, and ERBB2 alterations. A robust inverse association with RB1 mutations was observed in both cohorts. Although MTAP deletion appeared associated with lower TMB ( P < .01) and shorter OS in EGFR -mutated lung cancer (median 18.5 v 31.4 months, P < .01), these associations were largely attributable to enrichment of oncogenic drivers and concurrent CDKN2A loss, respectively. CONCLUSION: MTAP -deleted thoracic tumors exhibit reproducible clinical and molecular features across populations. Our findings support the rational, globally applicable development of MTAP -targeted synthetic lethal strategies in thoracic malignancies, particularly in combination with molecular targeted agents.
- Open Access
- 29 April 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Molecular heterogeneity of ERBB2-altered cancers: A pan-cancer landscape across US and Japanese cohorts
Therapies targeting ERBB2 (HER2) are rapidly expanding toward tissue-agnostic indications. However, the diversity of ERBB2-altered tumors across different cancer types and populations remains poorly characterized. We performed a comprehensive pan-cancer molecular analysis of ERBB2-altered tumors using two large clinical genomic datasets: AACR Project GENIE (n = 210,640) and the nationwide Japanese comprehensive genomic profiling database (C-CAT; n = 80,600). Across all cancer types, the prevalence of ERBB2 mutations was 1.4% in GENIE and 2.2% in C-CAT, whereas ERBB2 amplification occurred in 2.1% and 6.5% of tumors, respectively. Kinase domain mutations such as L755S in breast cancer and Y772_A775dup in lung cancer were enriched in a cancer type-specific manner, while R678Q in the juxtamembrane domain was common in colorectal and gastroesophageal cancers. ERBB2 compound mutations were rare (<1% in both cohorts) and did not significantly impact overall survival in the cohort treated predominantly before the advent of novel HER2-selective targeted therapies. ERBB2 mutations and amplifications also displayed divergent co-mutational landscapes: mutations frequently co-occurred with ARID1A mutations, whereas amplifications were enriched for TP53 mutations and CCNE1 amplification. In colorectal cancer, ERBB2 mutations were associated with higher tumor mutational burden (TMB) and frequent KRAS co-mutations, while in lung adenocarcinoma, ERBB2 amplifications exhibited higher TMB and a heavier co-mutation burden. A survival analysis revealed that specific co-occurring alterations, including MAP2K1 mutations in colorectal cancer and CCNE1 amplification in breast cancer, were associated with distinct prognostic outcomes among ERBB2-amplified cases. Our findings demonstrate that "ERBB2-altered cancer" is not a homogenous entity. Optimizing precision oncology for ERBB2 requires integrating histological context, specific alteration types, and co-mutation profiles to guide therapeutic selection and overcome resistance.
- 29 April 2026
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Open AccessMolecular heterogeneity of ERBB2-altered cancers: A pan-cancer landscape across US and Japanese cohorts
Therapies targeting ERBB2 (HER2) are rapidly expanding toward tissue-agnostic indications. However, the diversity of ERBB2-altered tumors across different cancer types and populations remains poorly characterized. We performed a comprehensive pan-cancer molecular analysis of ERBB2-altered tumors using two large clinical genomic datasets: AACR Project GENIE (n = 210,640) and the nationwide Japanese comprehensive genomic profiling database (C-CAT; n = 80,600). Across all cancer types, the prevalence of ERBB2 mutations was 1.4% in GENIE and 2.2% in C-CAT, whereas ERBB2 amplification occurred in 2.1% and 6.5% of tumors, respectively. Kinase domain mutations such as L755S in breast cancer and Y772_A775dup in lung cancer were enriched in a cancer type-specific manner, while R678Q in the juxtamembrane domain was common in colorectal and gastroesophageal cancers. ERBB2 compound mutations were rare (<1% in both cohorts) and did not significantly impact overall survival in the cohort treated predominantly before the advent of novel HER2-selective targeted therapies. ERBB2 mutations and amplifications also displayed divergent co-mutational landscapes: mutations frequently co-occurred with ARID1A mutations, whereas amplifications were enriched for TP53 mutations and CCNE1 amplification. In colorectal cancer, ERBB2 mutations were associated with higher tumor mutational burden (TMB) and frequent KRAS co-mutations, while in lung adenocarcinoma, ERBB2 amplifications exhibited higher TMB and a heavier co-mutation burden. A survival analysis revealed that specific co-occurring alterations, including MAP2K1 mutations in colorectal cancer and CCNE1 amplification in breast cancer, were associated with distinct prognostic outcomes among ERBB2-amplified cases. Our findings demonstrate that "ERBB2-altered cancer" is not a homogenous entity. Optimizing precision oncology for ERBB2 requires integrating histological context, specific alteration types, and co-mutation profiles to guide therapeutic selection and overcome resistance.
- Open Access
- 11 March 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (3) , e70555
Long‐Term Follow‐Up of Pleuroparenchymal Fibroelastosis Associated With Crohn's Disease
Pleuroparenchymal fibroelastosis (PPFE) is a rare fibrosing interstitial lung disease that has been increasingly reported as a secondary condition following various underlying disorders including organ transplantation. However, reports on PPFE associated with inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, remain extremely limited. We report the case of a 70‐year‐old man with Crohn's disease who developed slowly progressive upper‐lobe‐predominant lung lesions. Based on the clinical course, including the development of platythorax and pneumomediastinum, as well as the characteristic pulmonary function impairment and radiological findings, the patient was clinically diagnosed with PPFE. PPFE secondary to Crohn's disease is exceedingly rare, and this case is valuable in that longitudinal radiological progression could be followed in detail. This case highlights the importance of recognising PPFE as a pulmonary complication of Crohn's disease and underscores the value of careful longitudinal assessment using serial imaging and pulmonary function tests.
- 11 March 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (3) , e70555
Open AccessLong‐Term Follow‐Up of Pleuroparenchymal Fibroelastosis Associated With Crohn's Disease
Pleuroparenchymal fibroelastosis (PPFE) is a rare fibrosing interstitial lung disease that has been increasingly reported as a secondary condition following various underlying disorders including organ transplantation. However, reports on PPFE associated with inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, remain extremely limited. We report the case of a 70‐year‐old man with Crohn's disease who developed slowly progressive upper‐lobe‐predominant lung lesions. Based on the clinical course, including the development of platythorax and pneumomediastinum, as well as the characteristic pulmonary function impairment and radiological findings, the patient was clinically diagnosed with PPFE. PPFE secondary to Crohn's disease is exceedingly rare, and this case is valuable in that longitudinal radiological progression could be followed in detail. This case highlights the importance of recognising PPFE as a pulmonary complication of Crohn's disease and underscores the value of careful longitudinal assessment using serial imaging and pulmonary function tests.